20 September 2023
20 September 2023
UK public sector doctor's pay is below that in Germany or the US, and ongoing strike action may lead to more emigration.
The Medidata Diversity Program aids in delivering a strategy to attain trial diversity according to regulatory needs.
The FDA wanted changes to the Phase I/II study designs investigating TSHA-120 in giant axonal neuropathy.
The first-in-human trial will investigate Boundless Bio’s BBI-355 as a single agent and in combination with targeted therapies.
Under the deal, FB849 plus Keytruda will be evaluated in a Phase I/II clinical trial for treating advanced solid tumour patients.
Full analysis data from the trial are due to be published by the end of this year.
The open-label trial will assess the efficacy and safety of IMPT-314 in R/R aggressive B-cell lymphoma patients.
The company announced positive topline results from the single-ascending dose stage 1 portion of the study earlier this year.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.
Give your business an edge with our leading industry insights.
